231 related articles for article (PubMed ID: 32404645)
1. Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review.
Stolniceanu CR; Nistor I; Bilha SC; Constantin V; Simona V; Matovic M; Stefanescu C; Covic A
Nucl Med Commun; 2020 Jul; 41(7):601-617. PubMed ID: 32404645
[TBL] [Abstract][Full Text] [Related]
2. Long-term Nephrotoxicity after PRRT: Myth or Reality.
Baum RP; Fan X; Jakobsson V; Yu F; Schuchardt C; Chen X; Zhang J
Theranostics; 2024; 14(2):451-459. PubMed ID: 38169589
[No Abstract] [Full Text] [Related]
3. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.
Sabet A; Ezziddin K; Pape UF; Reichman K; Haslerud T; Ahmadzadehfar H; Biersack HJ; Nagarajah J; Ezziddin S
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):505-10. PubMed ID: 24196919
[TBL] [Abstract][Full Text] [Related]
4. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors.
Bodei L; Kidd M; Paganelli G; Grana CM; Drozdov I; Cremonesi M; Lepensky C; Kwekkeboom DJ; Baum RP; Krenning EP; Modlin IM
Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):5-19. PubMed ID: 25273832
[TBL] [Abstract][Full Text] [Related]
5. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
6. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
Bodei L; Pepe G; Paganelli G
Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):347-51. PubMed ID: 20496546
[TBL] [Abstract][Full Text] [Related]
7. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).
Baum RP; Wang P; Jakobsson V; Zhao T; Schuchardt C; Khong PL; Zhang J
Theranostics; 2024; 14(1):133-142. PubMed ID: 38164147
[No Abstract] [Full Text] [Related]
8. Myeloid neoplasms after chemotherapy and PRRT: myth and reality.
Bodei L; Modlin IM; Luster M; Forrer F; Cremonesi M; Hicks RJ; Ezziddin S; Kidd M; Chiti A
Endocr Relat Cancer; 2016 Aug; 23(8):C1-7. PubMed ID: 27353035
[TBL] [Abstract][Full Text] [Related]
9. Correlation of dose with toxicity and tumour response to
Cremonesi M; Ferrari ME; Bodei L; Chiesa C; Sarnelli A; Garibaldi C; Pacilio M; Strigari L; Summers PE; Orecchia R; Grana CM; Botta F
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2426-2441. PubMed ID: 29785514
[TBL] [Abstract][Full Text] [Related]
10. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
[TBL] [Abstract][Full Text] [Related]
11. Nephrotoxicity after PRRT - still a serious clinical problem? Renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATATE and 90Y/177Lu-DOTATATE.
Kunikowska J; Królicki L; Sowa-Staszczak A; Pawlak D; Hubalewska-Dydejczyk A; Mikołajczak R
Endokrynol Pol; 2013; 64(1):13-20. PubMed ID: 23450442
[TBL] [Abstract][Full Text] [Related]
12. Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm.
Bober B; Saracyn M; Lubas A; Kolodziej M; Brodowska-Kania D; Kapusta W; Kaminski G
Nucl Med Rev Cent East Eur; 2022; 25(1):54-61. PubMed ID: 35137938
[TBL] [Abstract][Full Text] [Related]
13. Beta-emitting radionuclides for peptide receptor radionuclide therapy.
Parus JL; Mikolajczak R
Curr Top Med Chem; 2012; 12(23):2686-93. PubMed ID: 23339764
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up.
Duan H; Ferri V; Fisher GA; Shaheen S; Davidzon GA; Iagaru A; Mari Aparici C
Oncologist; 2022 Jun; 27(6):447-452. PubMed ID: 35641196
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of the available peptide receptor radionuclide therapy for neuroendocrine tumors: a meta-analysis.
Dannoon SF; Alenezi SA; Elgazzar AH
Nucl Med Commun; 2017 Dec; 38(12):1085-1093. PubMed ID: 28957840
[TBL] [Abstract][Full Text] [Related]
16. Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumours.
Almeamar H; Cullen L; Murphy DJ; Crowley RK; Toumpanakis C; Welin S; O'Shea D; O'Toole D
J Neuroendocrinol; 2022 Jun; 34(6):e13138. PubMed ID: 35485450
[TBL] [Abstract][Full Text] [Related]
17. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
Ranade R; Basu S
J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
[TBL] [Abstract][Full Text] [Related]
18. Polish experience in Peptide receptor radionuclide therapy.
Kunikowska J; Królicki L; Sowa-Staszczak A; Hubalewska-Dydejczyk A; Pawlak D; Mikolajczak R; Handkiewicz-Junak D; Szaluś N; Kamiński G; Cwikla J; Jakuciński M; Lukiewicz A; Kowalska A; Gut P
Recent Results Cancer Res; 2013; 194():467-78. PubMed ID: 22918776
[TBL] [Abstract][Full Text] [Related]
19. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
[TBL] [Abstract][Full Text] [Related]
20. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
Pach D; Sowa-Staszczak A; Kunikowska J; Królicki L; Trofimiuk M; Stefańska A; Tomaszuk M; Głowa B; Mikołajczak R; Pawlak D; Jabrocka-Hybel A; Hubalewska-Dydejczyk AB
Radiother Oncol; 2012 Jan; 102(1):45-50. PubMed ID: 21885142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
